Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Signals !!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(182)
•••
Comment by Chritterson Jul 19, 2021 11:13am
70 Views
Post# 33569155

RE:Signals !!!

RE:Signals !!!For someone that claims to be in the Armed Forses Jumping out of airplanes etc your definatly not very smart are ya? You sure as hell cant spell!! Give Robert a Hug for me


HighSkies2019 wrote: Lol lol....not losing faith ...frustrated yes ....just tired of waiting like most long investors ...unlike you and your friend always downing the stk over on the other board ....not sure if you and you and your buddy are shorters ...sure sounds like it the way you both knock the stk and other investors ...you boast about you voted no on rs which is fine...you both cry daily against investors that post anything positive on their personal opinion ... one day your selling the next your bragging about buying...yet you both seem to think that most names on all boards are all of the same person Drew ... this guy Drew really has your thoughts in a twist .. .what happen got kicked off another board lol


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities